2 news items
Zentalis Pharmaceuticals To Highlight Preclinical Data Demonstrating That WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity With KRAS(G12C) Inhibitors At AACR Annual Meeting 2024
ZNTL
2 Apr 24
inhibitors increased the duration of response versus single agent use. Together, these results support continued study of the potential for azenosertib
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
ZNTL
2 Apr 24
with KRASG12C inhibitors increased the duration of response versus single agent use. Together, these results support continued study of the potential
- Prev
- 1
- Next